Peptides for Weight Loss 2026: AOD-9604, Semaglutide, Tesamorelin & More

The weight loss peptide space has arguably seen more change in the past three years than in the previous two decades combined. The GLP-1 class—semaglutide and tirzepatide—has dominated headlines, but a range of other peptides continue to draw serious interest from clinicians and patients seeking more targeted fat-loss effects with different side effect profiles.

This guide breaks down the most clinically relevant peptides for weight loss in 2026, what the evidence actually shows, and what realistic outcomes look like.

Why Peptides for Weight Loss?

Weight loss peptides work through distinct mechanisms compared to stimulant-based diet drugs or caloric restriction alone. They can modulate growth hormone secretion, reduce appetite through ghrelin or GLP-1 pathways, improve metabolic rate at the cellular level, or target visceral fat specifically. The diversity of mechanisms means there is rarely a one-size-fits-all answer—the best peptide for a given patient depends on their metabolic profile, primary goals, and tolerance for side effects.

GLP-1 Receptor Agonists: Semaglutide and Tirzepatide

Semaglutide (brand names Ozempic, Wegovy) is now the most widely prescribed weight loss intervention in the United States. As a GLP-1 receptor agonist, it works by slowing gastric emptying, increasing satiety signaling to the brain, and reducing appetite. Clinical trials consistently show 10 to 15 percent total body weight loss over 68 weeks at the highest approved doses, with some participants achieving 20 percent or more.

Tirzepatide (Mounjaro, Zepbound) adds GIP receptor agonism to GLP-1 activity and produces even larger weight losses in trial data—15 to 22 percent in pivotal trials.

Both compounds are FDA-approved and available through standard prescribing channels. Compounded versions became widely available during supply shortages, though regulatory pressure on compounding pharmacies has intensified in 2025 and 2026. The most significant side effects are gastrointestinal: nausea, vomiting, constipation, and gastroparesis at higher doses. Muscle mass loss during rapid weight loss is an underappreciated concern; combining GLP-1 therapy with resistance training and adequate protein intake is strongly recommended.

For a detailed look at GLP-1 peptides, see our GLP-1 peptides guide.

AOD-9604: Targeted Fat Mobilization

AOD-9604 is a modified fragment of the human growth hormone molecule (amino acids 176–191), specifically the region responsible for GH's lipolytic (fat-breaking) effects. Unlike full HGH or GH secretagogues, AOD-9604 does not significantly raise IGF-1 levels, which means it avoids many of the metabolic concerns associated with elevated growth hormone.

Animal studies showed compelling fat loss results, and early human trials demonstrated favorable safety profiles. However, the pivotal Phase III trials for AOD-9604 as an obesity drug did not meet their efficacy endpoints when tested alone, and the drug did not receive FDA approval for obesity. This is a critical nuance: it does not mean AOD-9604 has no fat-loss effect, but it means the effect at standard doses was not large enough to clear the bar for pharmaceutical approval as a standalone treatment.

In clinical practice, AOD-9604 is typically used at doses of 300 to 500 mcg subcutaneously per day, often combined with other fat-loss or GH-stimulating peptides. Users and practitioners report modest but meaningful reductions in body fat—particularly visceral fat—over 8 to 12 weeks. It is best understood as a complement to diet and exercise rather than a standalone weight loss intervention. See our full AOD-9604 guide for dosing specifics.

Tesamorelin: FDA-Approved Visceral Fat Reduction

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) and holds FDA approval for reducing excess visceral abdominal fat in HIV-positive patients with lipodystrophy. It works by stimulating pulsatile GH release from the pituitary, which in turn increases lipolysis in visceral adipose tissue.

The FDA-approved indication is narrow, but tesamorelin's mechanism is directly relevant to the visceral fat accumulation that accompanies insulin resistance, metabolic syndrome, and normal aging. Off-label use for visceral fat reduction is growing among metabolic health clinicians, typically at doses of 1 to 2 mg per day by subcutaneous injection.

Clinical data shows significant reductions in visceral fat (measured by MRI) at 26 weeks, with approximately 15 to 20 percent reductions reported in trials. Unlike some GH secretagogues, tesamorelin has a well-characterized safety profile from its FDA approval process. Blood glucose monitoring is recommended because elevated GH levels can reduce insulin sensitivity. For more information see our tesamorelin guide.

CJC-1295 and Ipamorelin: The Classic GH Stack

CJC-1295 is a GHRH analog, and ipamorelin is a selective GH secretagogue that stimulates GH release without significantly raising cortisol or prolactin. Together, they produce a synergistic pulse of GH that mimics the body's natural nocturnal GH release pattern—amplitude is higher than either peptide alone.

The fat loss mechanism is indirect: sustained elevation of GH shifts the body toward fat oxidation as a fuel source, preserves lean muscle mass, and over months produces measurable changes in body composition. This is not a rapid-onset intervention. Most patients see meaningful changes in body composition after 3 to 6 months of consistent use, and the effect is most pronounced when combined with appropriate nutrition and resistance training.

Standard dosing is CJC-1295 (without DAC) at 100 to 200 mcg paired with ipamorelin at 100 to 200 mcg, injected subcutaneously 30 to 60 minutes before bed, 5 days per week. The bedtime timing takes advantage of the natural nocturnal GH surge. See our full guides on CJC-1295 and ipamorelin for more detail.

MOTS-c and Mitochondrial Metabolism

MOTS-c is a mitochondria-derived peptide that has attracted research attention for its role in metabolic regulation. It activates AMPK, a cellular energy sensor that shifts metabolism toward fat utilization and improves insulin sensitivity. Animal studies show dramatic protection against diet-induced obesity and metabolic syndrome with MOTS-c treatment, including effects that appear to partially mimic the metabolic benefits of exercise.

Human data is still limited, but early trials are underway. MOTS-c is not widely available through clinical channels in 2026 but is available as a research peptide. It represents one of the more scientifically interesting emerging options for metabolic health and weight management.

Realistic Expectations

The most important thing to understand about weight loss peptides is that none of them replace the fundamentals. Even semaglutide—with the strongest clinical evidence of any weight loss peptide—produces its best results when combined with behavioral intervention. Patients who regain weight after discontinuing GLP-1 agonists do so because the underlying energy balance and lifestyle factors were not addressed.

For GH-stimulating peptides like CJC/ipamorelin or tesamorelin, realistic expectations at 3 months include modest improvements in body composition—perhaps 2 to 5 percent reductions in body fat percentage, with lean mass preservation or modest gain. At 6 to 12 months, the cumulative effect becomes more apparent.

For GLP-1 agonists, 10 to 20 percent total body weight loss is achievable in motivated patients at full therapeutic doses over 12 to 18 months.

For a broader view of fat-loss peptide options, see our dedicated peptides for fat loss guide.

Frequently Asked Questions

Q: Which peptide is best for weight loss? GLP-1 agonists like semaglutide and tirzepatide produce the largest documented weight losses in clinical trials and are FDA-approved. For patients seeking a more targeted approach to visceral fat with less gastrointestinal burden, tesamorelin or CJC-1295/ipamorelin may be appropriate, though results are more modest and slower to appear.

Q: Is AOD-9604 effective for weight loss? AOD-9604 has demonstrated fat-mobilizing effects in research settings but did not meet the efficacy threshold for pharmaceutical approval as a standalone weight loss drug. In clinical practice it is used as part of a broader protocol and produces modest fat reduction, particularly when combined with caloric restriction and exercise.

Q: How long does it take for weight loss peptides to work? GLP-1 agonists typically produce noticeable appetite reduction within days to weeks, with significant weight loss apparent at 3 to 6 months. GH-stimulating peptides like CJC/ipamorelin produce more gradual body composition changes over 3 to 6 months of consistent use.

Q: Can you combine multiple weight loss peptides? Yes, combination protocols are commonly used in clinical practice. A common approach pairs a GH secretagogue (for body composition and metabolic effects) with a GLP-1 agonist (for appetite suppression). All combinations should be managed by a qualified provider with appropriate monitoring.

Q: Do weight loss peptides cause muscle loss? GLP-1 agonists used alone can contribute to muscle mass loss during rapid weight loss, which is why resistance training and adequate protein intake are critical. GH-stimulating peptides generally preserve or support lean mass gain, making them a useful complement to appetite-suppressant therapy.